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T-cell growth cytokinesitution is limited after HAART, maintaining the interest in adjunctive immune-
modulators. We compared in vitro the effects of the γ-chain T-cell growth cytokines IL-2, IL-4, IL-7 and IL-15
on cytomegalovirus-stimulated cell-mediated immunity. IL-2 and IL-15 increased cytomegalovirus-speciﬁc
lymphocyte proliferation in HAART recipients, whereas IL-4 and IL-7 did not. The boosting effect of IL-2 and
IL-15 on proliferation correlated with their ability to prevent late apoptosis. However, IL-2 increased the
frequency of cells in early apoptosis, whereas IL-15 increased the frequency of fully viable cells. Both IL-2 and
IL-15 increased cytomegalovirus-induced CD4+ and CD8+ T-cell proliferation and the synthesis of Th1 and
pro-inﬂammatory cytokines and chemokines. However, only IL-2 increased the frequency of regulatory T
cells and Th2 cytokine production, both of which have the potential to attenuate antiviral immune responses.
Overall, compared to other γ-chain cytokines, IL-15 had the most favorable proﬁle for boosting antiviral cell-
mediated immunity.
© 2008 Elsevier Inc. All rights reserved.IntroductionHighly active antiretroviral therapy (HAART) decreases the
incidence of opportunistic infections and increases CD4+ T cells in
HIV-infected patients. However, reconstitution of adaptive immune
responses is often incomplete as demonstrated by persistently poor
responses to vaccines (Lange et al., 2003; Weinberg et al., 2006a) and
the occasional occurrence of opportunistic infections, such as cyto-
megalovirus (CMV), herpes zoster, and disseminated tuberculosis in
individuals with N200 CD4+ cells/µl (Jacobson et al., 1997; Komanduri
et al., 2001; Lawn et al., 2005).
We previously reported that HAART recipients had multiple
abnormalities of the CMV-speciﬁc cell-mediated immunity (CMI)
(Weinberg et al., 2006b, 2001, 2003), including decreased prolifera-
tion of CMV-stimulated peripheral blood mononuclear cells (PBMC),
which inversely correlated with apoptosis of both resting and CMV-
stimulated PBMC (Weinberg et al., 2004). Both proliferation and
apoptosis improved after in vitro treatment with the viral serpin
crmA, which blocks caspase 8 and 9 activities, but not after cell death
receptor blockade, suggesting that the mitochondrial apoptotic path-
way was involved in the decreased CMV CMI. HIV infection has been
shown to directly or indirectly increase apoptosis via the intrinsic
mitochondrial pathway (Genini et al., 2001; Holm and Gabuzda,s Box C227, Denver, CO 80262,
einberg).
l rights reserved.2005), but other factors, such as insufﬁcient induction of bcl-2 or
analogous anti-apoptotic factors by T-cell growth cytokines may also
contribute to this effect (Pahwa et al., 2006; Petrovas et al., 2004;
Zaunders et al., 2003). Several cytokines, including the Th1 cytokines
IL-2 and IL-15, the Th0 cytokine IL-7, and the Th2 cytokine IL-4,
increase bcl-2 production and activate other cell survival mechanisms
by signaling through the common γ-chain receptor (Adachi et al.,
1996; Leonard, 2001). In addition, HIV infection has been associated
with abnormal IL-2, IL-7 and IL-15 production and/or function,
suggesting that exogenous addition of these cytokines may improve
immune functions (d'Ettorre et al., 2002; De Paoli, 2001; Ostrowski
et al., 2003; Sasson et al., 2006).
Due to the incomplete immune reconstitution resulting from
HAART, cytokines, chemokines and other immune mediators have
been administered to enhance immune responses of HIV-infected
subjects (De Paoli, 2001; Katlama et al., 2002; Keh et al., 2006;
Kuekrek et al., 2005; Lindemann et al., 2004; Martinez-Marino et al.,
2004; Sereti et al., 2004, 2002). In vivo administration of IL-2, in
addition to HAART, consistently increased CD4+ T-cell numbers, but
generally failed to augment pre-existing or to replace previously lost
antigen-speciﬁc CMI (De Paoli, 2001; Lindemann et al., 2004). IL-2
administration rarely increased responses to recall or neo antigens
(Kuekrek et al., 2005; Levy et al., 2006; Nacsa et al., 2005; Valdez et al.,
2003). Although the presence of IL-2 during primary antigenic
exposure may be required for the development of immunologic
memory (Weinberg and Merigan, 1988; Williams et al., 2006), IL-2
administration is also associated with an increase in the number of
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(AICD) in the presence of persistent antigen presentation (Anderson
et al., 2005; Malek and Bayer, 2004; Sereti et al., 2002), which may
contribute to the limited effect of IL-2 on reconstitution of adaptive
immunity of HIV-infected individuals (Nacsa et al., 2005).
IL-15 is a Th1 cytokine that shares many properties with IL-2,
including β- and γ-chain cellular receptors (Cornish et al., 2006; Dubois
et al., 2003). However, IL-15 also has speciﬁc effects including a marked
increase of memory CD8+ T-cell survival (Sato et al., 2007). IL-15 has
not been extensively studied in HIV-infected subjects, but IL-15
administration to SIV-infected macaques enhanced their immune
reconstitution (Picker et al., 2006).
IL-7 induces lymphopoiesis and peripheral T-cell homeostasis and
prolongs survival of memory and effector CD4+ and CD8+ cells (Fry and
Mackall, 2005; Picker et al., 2006; Rathmell et al., 2001). In addition,
IL-7 may increase cytotoxicity (Lum et al., 2004) and antigen-speciﬁc
IFNγ production (Jennes et al., 2002).
IL-4 also stimulates T-cell growth and proliferation and, like IL-2
and IL-15, can prevent AICD (Kennedy and Celis, 2006). IL-4, however,
is more likely to dampen than boost antiviral CMI (Wherry, 2004).
The goal of this study was to compare the effect of γ-chain
cytokines on apoptosis and CMV-speciﬁc CMI in HIV-infected
individuals and to determine the function of the T cells expanded
with the use of exogenous cytokines.
Results
Differential effect of T-cell growth cytokines on PBMC apoptosis and
CMV-speciﬁc proliferation
To test the hypothesis thatγ-chain receptor signaling is sufﬁcient to
decrease apoptosis and increase proliferation of PBMC from HIV-
infected subjects, we examined the ex-vivo effect of IL-2, IL-4, IL-7 and
IL-15 γ-chain cytokines on CMV-stimulated PBMC from HIV-infected
anduninfected subjects. Although these cytokines have commonγ-chain
receptor activity, they differ with respect to their overall function: IL-2
and IL-15 have Th1 properties, IL-7 has Th0 properties and IL-4 has Th2
properties. The experiments using PBMC from healthy volunteers
showed that all 4 cytokines signiﬁcantly increased proliferation
stimulated with mock-infected control antigen (average increase of
65,240, 4802, 9251 and 105,800 cpm for IL-2, IL-4, IL-7 and IL-15,
respectively; not depicted), but also CMV-speciﬁc proliferation, assessed
by the difference between 3H-thymidine incorporation in CMV and
control antigen-stimulated cultures (Fig. 1). IL-2, IL-7 and IL-15, but not
IL-4, increased proliferation of control antigen-stimulated PBMC from
HIV-infected subjects (averages of 16,300, 1836, 29,780 and 97cpm,
respectively; not depicted). Only the Th1 cytokines IL-2 and IL-15
signiﬁcantly increased CMV-speciﬁc proliferation of PBMC from HIV-
infected subjects on HAART (Fig. 1). Although there was no apparent
difference in thenet effects of IL-4 and IL-7 onCMV-speciﬁc proliferation
of PBMC from HIV-infected subjects, they resulted from different
mechanisms: IL-4 failed to increase proliferation of either CMV or
control antigen-stimulated PBMC, whereas IL-7 equally increased
proliferation of CMV- and control antigen-stimulated PBMC.
In cytokine-untreated cultures, CMV-stimulated proliferation of
PBMC from HIV-infected subjects was signiﬁcantly lower compared
with proliferation of PBMC from healthy individuals, with a mean
difference±SEM of 30,260±10,350cpm, p=0.008. To determine if
exogenous addition of cytokines brought the CMV-speciﬁc prolifera-
tive responses of PBMC from HAART recipients closer to the levels
observed in healthy subjects, we compared the CMV-speciﬁc cpm in
cytokine-treated cultures of HIV-infected subjects with the CMV-
speciﬁc cpm in cytokine-untreated cultures from healthy subjects. IL-
2 and IL-15 reduced the gap between HIV-infected and uninfected
subjects to 3808±13,170cpm (p=0.77) and 11,000±17,350cpm
(p=0.53), respectively. In contrast, exogenous IL-4 or IL-7 did notappreciably alter the CMV-speciﬁc proliferation difference between
HIV-infected and uninfected subjects (p of 0.01 and 0.05, respectively).
IL-15 ex-vivo treatment signiﬁcantly decreased apoptosis of CMV-
stimulated PBMC from HIV-infected (mean difference±SEM of 27±4%,
pb0.0001 paired T test) and healthy subjects (10±3%, p=0.006 paired
T test). IL-2 marginally decreased apoptosis of CMV-stimulated PBMC
from HIV-infected individuals (14±5%, p=0.06 paired T test), but not
of PBMC from healthy subjects (p=0.13 paired T test). IL-4 and IL-7
tended to decrease apoptosis of PBMC from HIV-infected and
uninfected subjects, but their effects did not reach statistical
signiﬁcance (p of 0.10 to 0.23, paired T test).
In cytokine-untreated cultures, apoptosis of CMV-stimulated
PBMC from HIV-infected subjects was signiﬁcantly higher compared
with uninfected controls with mean difference±SEM Annexin V+
PBMC of 23±3% (pb0.0001, unpaired T test). IL-15 ex-vivo treatment
reduced the gap in apoptosis between CMV-stimulated PBMC from
HIV-infected vs. uninfected individuals to mean difference±SEM of
6±5% (p=0.28, unpaired T test). IL-2 treatment had a less potent effect
on the excess apoptosis of HAART recipients compared with
uninfected controls (mean difference of 8±4%, p=0.06, unpaired T
test), whereas supplementation with exogenous IL-4 or IL-7 did not
appreciably change the difference in apoptosis between CMV-
stimulated PBMC cultures from HAART recipients vs. healthy subjects,
which remained highly signiﬁcant (p of 0.03 and 0.007, respectively).
These data indicated that IL-15 had the most potent anti-apoptotic
effect among the 4 cytokines evaluated in this study.
To investigate the association between the proliferative and anti-
apoptotic effects of ex-vivo cytokine treatment, we performed
correlation analyses between the cytokine-induced increase in log10
CMV-speciﬁc cpm with the decrease of Annexin V+PI+% PBMC.
Signiﬁcant positive correlations were found for IL-2 and IL-15
(p=0.01 each) but not for IL-4 or IL-7. These results suggested that
the lack of survival and proliferation of PBMC from HAART recipients
in response to CMV stimulation might be due to a Th1 cytokine
speciﬁc deﬁcit that could be corrected by the exogenous administra-
tion of IL-2 and evenmore so of IL-15. IL-4 and IL-7 did not appreciably
improve apoptosis or proliferation of CMV-stimulated PBMC from
HAART recipients, therefore all subsequent experiments addressed
differences and similarities between the effects of IL-2 and IL-15 only.
Effect of IL-2 and IL-15 on CMV-stimulated CD4+ and CD8+
cell proliferation and apoptosis
It was previously reported that the effect of IL-15 was more
prominent on CD8+ compared with CD4+ T cells. To determine if IL-15
preferentially elicited CD8+ cell proliferation in the presence of CMV
antigenic stimulation and to understand how this compared with the
effect of IL-2 on CMV-speciﬁc T-cell proliferation, we used CFSE dye
dilution, which enabled the differentiation between CD4+ and CD8+
cell proliferation.We used the CMV lysate as a stimulant after showing
that this particulate antigen induces both CD4+ and CD8+ cell
proliferation (Fig. 2).
The analysis of CMV or control antigen-stimulated PBMC cultures
from 8 HIV-infected subjects showed that there were no appreciable
differences in the effect of IL-2 or IL-15 on CD4+ vs. CD8+ cell
expansions (pN0.5 for either cytokine). Both cytokines increased cell
divisions in CMV or control antigen-stimulated cultures by approxi-
mately an order of magnitude. Compared with IL-2, IL-15 treatment
generated higher CMV-speciﬁc proliferation of CD4+ (mean±SEM of
11±3% vs. 4±3%, p=0.05) and CD8+ cells (8±2% vs. 1±2%, p=0.05),
suggesting that IL-15 may have a more discriminative antigen-
enhancing effect compared with IL-2 (Fig. 3).
Neither IL-2 nor IL-15 exogenous administration appreciably
changed viability of control antigen-stimulated PBMC from 6 donors
equally distributed between HIV-infected and uninfected individuals
(mean±SEM viability of 44±7%, 46±5% and 51±5% in untreated, IL-2-
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repeated measures; not depicted). In contrast, in CMV-stimulated
cultures, IL-15 exogenous administration signiﬁcantly increased the
percentage of viable T cells to 48±5% compared with 40±6% in
cytokine-untreated cultures (p=0.005) and 43±5% in IL-2-treatedcultures (p=0.002; Fig. 4). In contrast, viability of IL-2-treated and
cytokine-untreated T cells was not appreciably different. IL-2 treat-
ment resulted in a signiﬁcantly higher percentage of cells in early
apoptosis (15±1%) compared with cytokine-untreated and IL-15-
treated lymphocytes (13±1% each, p=0.05). IL-2 and IL-15 treatment
Fig. 2. CD4+ and CD8+ cell expansions in cultures stimulatedwith inactivated CMV antigen. The plots represent typical examples of CFSE-measured proliferation in HIV-infected (right
2 columns) and uninfected (left 2 columns) subjects. PBMC are labeledwith CFSE prior to in vitro culture and uptake of CD4+ and CD8+ cells is veriﬁed after individually gating on each
cell population (upper row). CFSE content is measured again after 6 days of in vitro stimulation with CMV (bottom row) and mock-infected control antigen (middle row). The plots
show very few dividing cells (CFSElo) in mock-infected control-stimulated cultures, but a signiﬁcant proportion of CD4+ and CD8+ cell divisions in CMV-stimulated PBMC.
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±6% in untreated cultures to 23±3% and 23±4% in IL-2- and IL-15-
treated cultures, respectively (p=0.005 and 0.006, respectively).
Effect of IL-2 and IL-15 on the frequency of regulatory T cells (Tregs)
IL-2 was previously shown to increase CD4+CD25+FoxP3+ Tregs.We
hypothesized that a diverse effect of IL-2 vs. IL-15 on Tregs may
contribute to the differential effect of these cytokines on apoptosis and
antigen-speciﬁc proliferation of CMV-stimulated PBMC. The effect of
IL-2 and IL-15 on the frequency of Tregs was investigated using PBMC
from 8 HIV-infected subjects on HAART (median CD4+ numbers=340Fig. 1. Effect of T-cell growth cytokines on CMV-speciﬁc proliferation and apoptosis of PBM
subjects (median CD4=352 cells/µl; median plasma HIV RNAb400 copies/ml) and 18 heal
between PWM cpm/control antigen cpm ≥5. Bars represent means and SEM of untreated (w
are depicted in the ﬁrst, second, third and fourth row, respectively. The ﬁrst column shows
antigen- from CMV-stimulated PBMC. The second column shows apoptosis, measured by
association between the cytokine-induced increase in proliferation (delta log10CMV cpm, cal
PBMC cultures) vs. decrease in late apoptosis (delta % apoptosis, calculated by the differen
cultures). The data in the third columnwere derived from 9 to 12 experiments using PBMC f
cytokine-treated with untreated cultures in the same group of subjects (continuous horizo
(interrupted lines); and linear regression for association analysis. All data passed normalitycells/µl and plasma HIV RNAb400 copies/ml; Fig. 5). We limited these
experiments to HIV-infected donors because these constitute the
target population for a potential therapeutic application. IL-2-treated
cultures of CMV-stimulated PBMC had higher frequencies of CD4+
CD25+FoxP3+ Tregs compared with untreated (mean difference=5%,
p=0.03) or with IL-15-treated cultures (mean difference=4.6%,
p=0.04). IL-2 also increased the frequency of CD8+CD25+FoxP3+ cells
compared with untreated (mean difference=8%, p=0.03) or with IL-
15-treated cultures (mean difference=7.4%, p=0.05). Addition of
exogenous IL-15 did not appreciably increase the frequency of CD4+
CD25+FoxP3+ or CD8+CD25+FoxP3+ Tregs compared with untreated
cultures (p=0.4 for either comparison).C from HIV-infected and uninfected subjects. Data were derived from 36 HIV-infected
thy individuals. All PBMC cultures had a positive response to PWM deﬁned by a ratio
hite) and cytokine-treated (black) PBMC cultures. The effects of IL-2, IL-4, IL-7 and IL-15
proliferation (CMV cpm) calculated by subtracting the 3H-Thy incorporation of control
the frequency of Annexin V+PI+ CMV-stimulated PBMC. The third column shows the
culated by the difference between the log10CMV cpm in cytokine-treated and untreated
ce between % Annexin V+PI+ CMV-stimulated PBMC in cytokine-untreated vs. treated
rom HIV-infected subjects. p values were derived from paired T tests for comparisons of
ntal lines), unpaired T tests for comparisons of HIV-infected with uninfected subjects
distribution test.
Fig. 3. Effect of IL-2 and IL-15 on CMV or control antigen-stimulated expansion of CD4+
and CD8+ PBMC from HIV-infected subjects on HAART. The bars represent means and
SEM of results derived from 8 HAART recipients (median CD4=322 cells/µl; median
plasma HIV RNAb400 copies/ml) of CMV-speciﬁc CFSElo T cell %. p values, calculated by
paired T test, are noted above the horizontal lines that connect the bars representing the
cell populations involved in the comparison.
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CMV-stimulated PBMC from HIV-infected subjects
Cytokine production was used to assess additional functional char-
acteristics of CMV-stimulated PBMC. Th1 and Th2 cytokines and chemo-
kines were measured in supernatants of CMV or control antigen-
stimulated PBMC from 22HIV-infected subjects onHAARTwithmedian
CD4+ cells=315 cells/µl and median plasma HIV RNAb400 copies/mlFig. 4. Comparative effect of IL-2 and IL-15 on apoptosis of CMV-stimulated PBMC from HIV-i
late apoptotic cells were measured by the % events in lower left, lower right and upper righ
lower and right upper quadrant. Data in panel B represent paired experiments of CMV-stimul
RNAb400 copies/ml) treated ex-vivowith IL-2 (light grey), IL-15 (dark grey), and no exogenou
late apoptotic PBMC were deﬁned as Annexin V−PI−, Annexin V+PI−, and Annexin V+PI+ cells(Fig. 6). The data, expressed as differences between CMV or control
antigen-stimulated cultures treated with IL-2, IL-15 or no cytokine,
showed that both IL-2 and IL-15 signiﬁcantly increased the Th1
cytokines IFNγ, TNFα and the chemokine RANTES (pb0.05, paired T
tests). For MIP-1α, only the boosting effect of IL-15 reached statistical
signiﬁcance (p=0.04). In contrast, IL-2, but not IL-15, signiﬁcantly
increased the production of Th2 cytokines including IL-4, IL-5, IL-10 and
IL-13 (pb0.01, paired T tests). IL-2 had its largest effect on IL-5 pro-
duction, which increased frommean±SEM of 5±0.7 pg/ml in untreated
cultures to 114±34 in IL-2-treated PBMC cultures, followed by IL-13, IL-
10 and IL-4. The amount of IL-4 measured in culture supernatants was
small and so was the difference between untreated and IL-2 treated
PBMC. However, the consistency of the effect of IL-2 across all Th2
cytokines together with the fact that there was no IL-4 detected in the
culture medium or in the supernatant of the PBMC stimulated with
control antigen suggests that these differences were real. The biologic
signiﬁcance of such small differences is difﬁcult to ascertain.
The effect of IL-2 and IL-15 on PBMC from 4 healthy individuals
(data not depicted) was consistent with the ﬁndings of HIV-infected
subjects. Both cytokines signiﬁcantly increased the secretion of TNFα,
RANTES and IL-10, but only IL-2 signiﬁcantly increased IL-5 and IL-13
production.
Discussion
In vitro measures of CMV-speciﬁc CMI are signiﬁcantly lower in
HIV-infected subjects on HAART compared with healthy individuals.
We sought to determine if any of 4 γ-chain cytokines IL-2, IL-4, IL-7nfected subjects on HAART. Panel A shows a typical scatter plot. Live, early apoptotic and
t quadrants, respectively. Total apoptosis was measured by the sum of % events in right
ated PBMC from 8 HIV-infected subjects (median CD4=322 cells/µl; median plasma HIV
s cytokines (white). Bars and lines representmeans and SEM. Viable, early apoptotic and
, respectively. p values were derived by paired T test.
Fig. 5. Comparative effect of IL-2 and IL-15 on CD4+ and CD8+ Treg frequencies in PBMC fromHIV-infected subjects on HAART. Panel A shows a typical scatter plot. Panel B presents the
data from 8 subjects (median CD4=340 cells/µl; median plasma HIV RNAb400copies/ml). Lines connect results of the same donor.
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Fig. 6. Comparative effect of IL-2 and IL-15 on CMV-stimulated cytokine and chemokine production of PBMC from HIV-infected subjects on HAART. Bars represent means and SEM of
cytokine or chemokine concentrations in CMV-stimulated PBMC culture supernatants after subtraction of concentrations in control antigen-stimulated PBMC from 22 HAART
recipients (median CD4=315 cells/µl; median plasma HIV RNAb400 copies/ml). Asterisks indicate signiﬁcant differences between cytokine-treated and untreated cultures (pb0.05
by paired T test).
54 J. Patterson et al. / Virology 378 (2008) 48–57and IL-15 could boost CMV-speciﬁc CMI responses of HAART
recipients. We found that IL-2 and IL-15 increased CMV-speciﬁc
proliferation measured by 3H-thymidine incorporation and CFSE
dilution. Furthermore, IL-2 and IL-15 in vitro supplementationsubstantially decreased the gap in proliferation between CMV-
stimulated PBMC from HIV-infected subjects on HAART and healthy
individuals. In contrast, IL-4 or IL-7 did not appreciably increase
CMV-speciﬁc proliferation of PBMC from HIV-infected subjects.
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liferation of PBMC from healthy donors, underscoring some of the
differences in immune functions between HIV-infected individuals
on HAART and healthy subjects.
IL-4 failed to enhance proliferation of CMV- or control antigen-
stimulated PBMC from HIV-infected subjects, but enhanced CMV-
stimulated proliferation of PBMC from healthy donors. This suggests
that the IL-4 receptors or their downstream pathways may be
saturated in cultured T cells from HIV-infected subjects. Others have
noted a Th2 bias in the immune response of HIV-infected subjects
before the advent of HAART (Wasik et al., 1997) and it is conceivable
that this may not be reverted with therapy.
IL-7 had a similar proliferative effect on antigen-stimulated vs.
unstimulated PBMC from HIV-infected subjects. This ﬁnding may not
be unexpected considering that IL-7 is important for the survival of
both naive and memory T cells (Kondrack et al., 2003; Li et al., 2003;
Sun et al., 2006; Vassena et al., 2007). However, IL-7 favored CMV-
speciﬁc proliferation of PBMC from healthy individuals, suggesting
that HIV infection alters the ability of PBMC to respond to IL-7. Several
lines of investigation also support this conclusion: 1) HIV-infected
patients have increased levels of circulating IL-7 associated with
reduced IL-7 receptor-α expression (Sasson et al., 2006); 2) IL-7
increases Fas-mediated apoptosis in the context of HIV infection
(Fluur et al., 2007); and 3) IL-7 is not necessary for the survival of
memory CD8+ cells (Klonowski et al., 2006), which represent an
important contingent among the PBMC that proliferate in response to
CMV stimulation in HIV-infected subjects. These and our data indicate
that therapeutic use of IL-7 is unlikely to increase antigen-speciﬁc
immune responses of HAART recipients.
The increase of CMV-speciﬁc proliferation of PBMC from HIV-
infected subjects generated by IL-2 or IL-15 in vitro supplementation
signiﬁcantly correlated with the ability of each cytokine to protect the
PBMC against late apoptosis. However, IL-15 had a more robust anti-
apoptotic effect than IL-2 in PBMC cultures from HIV-infected and
uninfected subjects. In addition, IL-15 arrested PBMC progression to
apoptosis in earlier stages compared with IL-2, increasing the
proportion of fully viable cells, whereas IL-2 prevented progression
from early to late apoptosis, suggesting a mechanistic difference
between the 2 cytokines. Since apoptosis is increased by in vitro
antigenic stimulation (Weinberg et al., 2003), the ability of IL-15 to
prevent apoptosis may account for its greater effect on CMV-induced
proliferation by comparison with IL-2. This observation is also
consistent with the notion that IL-15 has a unique role in prolonging
T-cell survival and maintaining immunologic memory (Alpdogan
et al., 2005; Berard et al., 2003; Picker et al., 2006; Schluns et al.,
2002). The robust anti-apoptotic effect of IL-15 may allow HIV-
infected patients with chronic antigenic stimulation to maintain high
levels of antigen-speciﬁc T cells.
IL-2, but not IL-15 signiﬁcantly increased the proportion of CD4+
Tregs in CMV-stimulated cultures from HIV-infected or uninfected
subjects. This is in accordance with previous reports of increased in
CD4+ Tregs in patients treated with IL-2 (Sereti et al., 2002). We also
showed that IL-2 increased CD8+CD25+FoxP3+, which may also have
Treg properties (Endharti et al., 2005). The ability of IL-15 to stimulate
CMI without inducing excess Treg expansion may be an advantage for
its use as an immune-stimulator in HIV-infected individuals.
IL-15, compared with IL-2, increased the production of a slightly
broader array of Th1 cytokines and chemokines by CMV-stimulated
PBMC from HIV-infected subjects, suggesting that IL-15 may have a
more robust boosting effect on antiviral CMI. In contrast, IL-2, but not
IL-15, signiﬁcantly increased Th2 cytokine production by CMV-
stimulated PBMC from HIV-infected subjects on HAART. Since Th2
cytokines have been previously shown to divert the immune response
from Th1 to Th2 and IL-10 is also known to mediate Treg activity, the
Th2-enhancing effect of IL-2 may attenuate antiviral defenses. This
effect may also contribute to the failure of IL-2 administration toHAART recipients to boost their antigen-speciﬁc CMI when the
antigen predominantly stimulates Th1 responses.
Taken together, our data indicate that IL-15 therapeutic adminis-
tration is more likely than IL-2 or IL-7 to facilitate recovery of adaptive
immune responses of HIV-infected individuals. Clinical studies are
warranted to further assess its therapeutic value.
Subjects and methods
Subjects
This study enrolled 62 CMV-seropositive individuals, including 36
HIV-infected subjects on HAART and 26 HIV-uninfected controls,
according to the norms of the Colorado Multiple Institutional Review
Board. Other inclusion criteria for HIV-infected subjects were HAART,
deﬁned as ≥3 antiretrovirals including ≥2 classes, for ≥3months; CD4+
b100 cells/µl before HAART and ≥100 cells/µl at enrollment. At blood
draws, the median duration of HAART was 18 months; the median
CD4+ cell count was 340 cells/µl with a maximum of 1309 cells/µl; and
the median and upper quartile plasma HIV RNA was b102.6 copies/ml
with a maximum of 105.3.
Reagents
CMV or control antigens were prepared by glycine extraction and
UV inactivation of CMV AD169- and mock-infected human lung
ﬁbroblasts, respectively. Although inactivated, the CMV-infected cell
lysate stimulates both CD4+ and CD8+ T cells similar to the responses
to other inactivated virions (Burgdorf et al., 2007; Larsson et al., 2002;
Rutebemberwa et al., 2007). Recombinant human IL-2, IL-4, IL-7, and
IL-15 were purchased from R&D Systems. Staining reagents were as
follows: carboxyﬂuorescein diacetate, succinimidyl ester (CFSE,
Molecular Probes), PerCP-conjugated anti-CD4 (anti-CD4-PerCP) and
anti-CD8-PerCP mouse mAbs (Becton Dickinson); and anti-CD25-APC
and anti-FoxP3-FITC (eBiosciences).
Specimen processing and cryopreservation
PBMC from heparinized blood, separated by Ficoll/Hypaque
gradient (Sigma) centrifugation, were cryopreserved as previously
described (Weinberg et al., 2000) at 107 cells/ml in 10% dimethyl
sulfoxide (Sigma)-containing fetal bovine serum (Gemini Bio-
Products).
Lymphocyte proliferation
This was performed using cryopreserved PBMC as previously
described (Weinberg et al., 2001). Stimulation medium consisted
of RPMI 1640 with glutamine (Gibco), 10% human AB serum (Nabi)
and 1% antibiotics (Gibco). 106 PBMC/ml were stimulated with
CMV antigen at a 1:200 ﬁnal dilution in quadruplicate wells or
culture tubes. Mock-infected antigen and pokeweed mitogen
(Sigma) were used as negative and positive controls at ﬁnal
dilutions of 1:200 and 10 µg/ml, respectively. Recombinant human
IL-2, IL-4, IL-7, and IL-15 in concentrations pre-determined to
providemaximum stimulation (3.3 ng/ml, 2.5 ng/ml, 3.3 ng/ml and
2.5 ng/ml, respectively) were added to the stimulation medium. To
measure proliferation, 6-day cultures maintained at 37 °C and 5%
CO2, were pulsed with 3H-thymidine (Perkin Elmer) for 6 h,
harvested and counted using Uniﬁlter plates (Perkin Elmer) and a
microplate scintillation counter (Packard). CMV-speciﬁc prolif-
eration was calculated by subtracting the median counts per
minute (cpm) measured in the mock-infected control wells from
the median cpm of the CMV-stimulated wells. For ﬂow cytometric
assays, cells were harvested, washed and stained as described
below.
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TACS Annexin V-FITC apoptosis detection kit (R&D Systems) was
used for measurement of PBMC apoptosis. Samples containing 105 to
106 PBMC were centrifuged at 500 g for 10 min, washed with cold
phosphate-buffered saline (PBS), and resuspended in 100 µl of Annexin
V Incubation Reagent containing Annexin V-FITC and propidium
iodide (PI). After 15 min of incubation in the dark, 400 µl of binding
buffer was added. Samples were analyzed using a FACSCalibur ﬂow
cytometer and CellQuest software (Becton Dickinson).
T-cell phenotypic characterization
Stimulated PBMC were washed in PBS and incubated with the
appropriate surface marker mAb for 30 min at room temperature. For
intracellular staining, PBMC were then permeabilized and ﬁxed using
Cytoﬁx/Cytoperm (BD Pharmingen) for 20 min at 4 °C, washed and
stained with the appropriate reagents. After washing with PBS, PBMC
were analyzed in real timewith a FACSCalibur instrument and CellQuest
software (BD Biosciences). The number of events collectedwas ≥10,000.
CFSE dilution assays
PBMC were labeled with 0.5 µM CFSE (Molecular Probes) in 0.1%
bovine serum albumin PBS for 10 min at 37 °C. Staining was quenched
with cold 10% human AB serum in RPMI. An aliquot of PBMC was
removed for baseline ﬂow analysis and the remaining cells were
stimulated with CMV or control antigen for 6 days, after which PBMC
were washed in PBS, stained with CD4 and CD8 surface markers and
analyzed by ﬂow cytometry as described above.
Cytokine and chemokine detection
Inducible cytokines and chemokines were measured in the super-
natants of 6-day CMV or mock-infected control antigen-stimulated
PBMC using Human Cytokine Antibody Bead Kits (Biosource) accord-
ing to the manufacturer's instructions. CMV-speciﬁc production was
expressed as the difference in concentration between CMV and mock-
infected control antigen-stimulated cultures.
Statistical analysis
Analysis was performed using Instat3 and Prism4 (GraphPad)
software. Two-tailed parametric T tests or ANOVA were used for the
statistical analyses after verifying that the data were normally
distributed. Signiﬁcance was deﬁned by p≤0.05.
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